HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ranjit John Kenneth Liao Lyle Joyce Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by John, R. Articles by Boyle, A. Search for Related Content PubMed Articles by John, R. Articles by Boyle, A. Related Collections Mechanical Circulatory Assistance Transplantation - heart

J Thorac Cardiovasc Surg 2008;136:1318-1323
© 2008 The American Association for Thoracic Surgery

Evolving Technology

Low thromboembolic risk for patients with the Heartmate II left ventricular assist device

^a Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, Minn
^b Department of Surgery and Division of Cardiology, University of Minnesota, Minneapolis, Minn

Received for publication July 31, 2007; revisions received November 14, 2007; accepted for publication December 18, 2007.

^_* Address for reprints: Ranjit John, MD, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN 55455. (Email: johnx008{at}umn.edu).

Objective: Thromboembolic events can occur in up to 20% of patients with a left ventricular assist device. The aggressive use of anticoagulation with newer continuous-flow devices has potentially increased the risk of postoperative bleeding. The predecessor of the HeartMate II left ventricular assist device, the HeartMate XVE (Thoratec Corp, Pleasanton, Calif), was associated with an extremely low thromboembolic risk, even without anticoagulation, because of its unique textured surfaces. Even though several areas of the HeartMate II are textured, a protocol was adopted for this new axial flow pump requiring long-term anticoagulation with warfarin. In our study, we investigated whether the HeartMate II left ventricular assist device is associated with a similarly low thromboembolic risk as the HeartMate XVE.

Methods: At our institution, 45 patients (mean age, 57.24 ± 14.2 years) underwent implantation of the HeartMate II; 30 underwent bridge-to-transplantation therapy, 7 underwent destination therapy, and 8 underwent left ventricular assist device exchange for a failed XVE left ventricular assist device. Total duration of HeartMate II support was 352.13 patient-months (mean duration, 7.2 ± 5.2 months). All 45 patients were treated postoperatively with warfarin and aspirin. We recorded use of these 2 medications and monthly international normalized ratios. Prospectively, we also monitored patients for any clinical thromboembolic events and for pump thrombus.

Results: Of our 45 study patients, 41 had a mean international normalized ratio of less than 2.0; of those 41 patients, 21 had a mean international normalized ratio of less than 1.6. Because of recurrent gastrointestinal bleeding episodes, 7 patients discontinued warfarin for a total duration of 39.1 patient-months. During the entire period of HeartMate II support, we noted 1 thromboembolic event. In addition, another patient had a suspected left ventricular assist device pump thrombus that resolved with a high-intensity heparin anticoagulation protocol (international normalized ratio, 1.3).

Conclusions: Our preliminary single-center analysis suggests that the HeartMate II is associated with an extremely low thromboembolic risk and with less stringent requirements for anticoagulation. Selected patients at high risk for bleeding can be safely followed with either no or extremely low anticoagulation requirements for prolonged periods.

This article has been cited by other articles:

				S. E. A. Felix, J. R. Martina, J. H. Kirkels, C. Klopping, H. Nathoe, E. Sukkel, N. Hulstein, F. Z. Ramjankhan, P. A. F. M. Doevendans, J. R. Lahpor, et al. Continuous-flow left ventricular assist device support in patients with advanced heart failure: points of interest for the daily management Eur J Heart Fail, February 3, 2012; (2012) hfs012v1. [Abstract] [Full Text] [PDF]

				T. Murakawa, T. Murayama, J. Nakajima, and M. Ono Lung lobectomy in a patient with an implantable left ventricular assist device Interact CardioVasc Thorac Surg, December 1, 2011; 13(6): 676 - 678. [Abstract] [Full Text] [PDF]

				J. Suarez, C. B. Patel, G. M. Felker, R. Becker, A. F. Hernandez, and J. G. Rogers Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices Circ Heart Fail, November 1, 2011; 4(6): 779 - 784. [Full Text] [PDF]

				R. John, F. Kamdar, P. Eckman, M. Colvin-Adams, A. Boyle, S. Shumway, L. Joyce, and K. Liao Lessons Learned From Experience With Over 100 Consecutive HeartMate II Left Ventricular Assist Devices Ann. Thorac. Surg., November 1, 2011; 92(5): 1593 - 1600. [Abstract] [Full Text] [PDF]

				Y. Topilsky, T. Hasin, J. K. Oh, D. D. Borgeson, B. A. Boilson, J. A. Schirger, A. L. Clavell, R. P. Frantz, R. Tsutsui, M. Liu, et al. Echocardiographic Variables After Left Ventricular Assist Device Implantation Associated With Adverse Outcome Circ Cardiovasc Imaging, November 1, 2011; 4(6): 648 - 661. [Abstract] [Full Text] [PDF]

				R. John, Y. Naka, N. G. Smedira, R. Starling, U. Jorde, P. Eckman, D. J. Farrar, and F. D. Pagani Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial Ann. Thorac. Surg., October 1, 2011; 92(4): 1406 - 1413. [Abstract] [Full Text] [PDF]

				D. Jennings, J. McDonnell, and J. Schillig Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: A pilot study J. Thorac. Cardiovasc. Surg., July 1, 2011; 142(1): e1 - e2. [Full Text] [PDF]

				A. Tiede, J. H. Rand, U. Budde, A. Ganser, and A. B. Federici How I treat the acquired von Willebrand syndrome Blood, June 23, 2011; 117(25): 6777 - 6785. [Abstract] [Full Text] [PDF]

				J. M. Schaffer, G. J. Arnaoutakis, J. G. Allen, E. S. Weiss, N. D. Patel, S. D. Russell, A. S. Shah, and J. V. Conte Bleeding Complications and Blood Product Utilization With Left Ventricular Assist Device Implantation Ann. Thorac. Surg., March 1, 2011; 91(3): 740 - 749. [Abstract] [Full Text] [PDF]

				C. R. Ensor, C. A. Paciullo, W. D. Cahoon Jr, and P. E. Nolan Jr Pharmacotherapy for Mechanical Circulatory Support: A Comprehensive Review Ann. Pharmacother., January 1, 2011; 45(1): 60 - 77. [Abstract] [Full Text] [PDF]

				D. L. Jennings, R. M. Chambers, and J. M. Schillig The Pharmacotherapy of the HeartMate II, a Continuous Flow Left Ventricular Assist Device, in Patients with Advanced Heart Failure: Integration of Disease, Device, and Drug Ann. Pharmacother., October 1, 2010; 44(10): 1647 - 1650. [Abstract] [Full Text] [PDF]

				C. M. Bhamidipati, G. Ailawadi, J. Bergin, and J. A. Kern Early thrombus in a HeartMate II left ventricular assist device: A potential cause of hemolysis and diagnostic dilemma J. Thorac. Cardiovasc. Surg., July 1, 2010; 140(1): e7 - e8. [Full Text] [PDF]

				S. E. Sandner, D. Zimpfer, P. Zrunek, A. Rajek, H. Schima, D. Dunkler, M. Grimm, E. Wolner, and G. M. Wieselthaler Renal Function and Outcome After Continuous Flow Left Ventricular Assist Device Implantation Ann. Thorac. Surg., April 1, 2009; 87(4): 1072 - 1078. [Abstract] [Full Text] [PDF]